-
Bangladesh Test cricket reboot delivers in style with historic win
-
Ukraine badminton star: 'How can you feel normal when bombs are falling?'
-
Virgin moves closer to launching Eurostar rival in 2030
-
Rain brings respite as Belgium wrestles massive wildfire
-
Indian marble waste dump becomes unlikely tourist attraction
-
Most stocks rise as US data ease rate fears but fuel economic worries
-
Coach says Australia 'let standards slip' in shock Bangladesh loss
-
India take control of Galle Test as Sri Lanka slump to 99-5
-
Hawaii recovery efforts begin as Lala downgraded, moves west
-
Australia's mushroom murderer appeals conviction
-
Food safety crackdown snares Mumbai's famed restaurants
-
The Nigerian fishing community being eaten up by the Atlantic
-
Trump says US scaling back military drills with Seoul hours before start
-
Kushner to meet Netanyahu after talks with Hamas on Gaza plan
-
Nearly 13,000 displaced after deadly Indonesian quake
-
Photos, memories all that remain for Colombia's bereaved after quake
-
Axe hangs over Australian batters after Darwin 'disaster'
-
Sabalenka squeezes out win on sixth match point in Cincinnati
-
Is this cave in Turkey where Homer wrote 'The Odyssey'?
-
Trump says US scaling back military drills with South Korea hours before start
-
Winning back walls from gangs, artists fill El Salvador's towns with color
-
Jason Arday: UK academic who died amid plagiarism storm
-
Opening arguments expected in Tupac murder trial
-
Sabbath cafe clash lays bare Israel faultlines
-
As machinery removes rubble, hopes for survivors from Colombian quake dwindle
-
SEG Announces 2026 Interim Results
-
Caledonia Mining Corporation Plc: Director Shareholding Notification
-
HM Exploration Commences Borehole & Surface EM Surveys at Lewis Pilley's
-
First Class Metals PLC Announces Application for OTCID Quotation
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - August 17
-
Gold Roth IRA: How It Works, Rules, Taxes, Fees, and What Investors Should Know in 2026 (Guide Released)
-
Top-ranked Scheffler powers to PGA St. Jude Championship victory
-
Trump says US scaling back military drills with South Korea
-
Jacquet scores on Liverpool debut in friendly win over Como
-
Zambia's Hichilema takes early lead in reelection bid
-
Hawaii's Big Island begins recovery efforts as Hurricane Lala downgrades, moves west
-
Sabalenka squeezes out a win on sixth match point in Cincinnati
-
Spidey swings high for third weekend in N. American box office
-
Duplantis dominant, Hunt hits four and Asher-Smith makes history
-
Eagle and late birdie lift Jeeno to LPGA Portland Classic win
-
Spanish soldier dies in Aragon wildfire
-
Duplantis masterclass for fourth Euro pole vault title
-
PSG beaten by Lens in French Champions' Trophy
-
Records for Asher-Smith, Hunt as Britain win 4x100m mixed relay
-
Rybakina, Andreeva race into Cincinnati third round
-
Barcelona reach deal with Man City to sign Rodri
-
Amy Hunt bags fourth Euro gold as Britain win 4x100m mixed relay
-
Misery for Maresca as Man City make dismal start to life after Guardiola
-
Spanish soldier dies in Aragon wildfire: regional leader
-
Strikes kill 19 in Russia and Ukraine
From Covid to cancer: High hopes for Nobel mRNA vaccines
The coronavirus pandemic brought global renown to the mRNA technology that underpins vaccines from Pfizer/BioNTech and Moderna, and on Monday earned a Nobel Prize for two scientists who have been key to its development.
Katalin Kariko of Hungary and Drew Weissman of the United States won the Nobel Medicine Prize for their work on "nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19".
These types of jabs are new but researchers have been working for decades to try to figure out how to use messenger RNA (ribonucleic acid) for other vaccinations and to treat illnesses from AIDS to cancer.
- How does it work? -
Messenger RNA's job in the body is to help deliver specific instructions from DNA to cells.
In the case of the Pfizer/BioNTech and Moderna jabs, lab-generated mRNA tells human cells to create antigens -- proteins that are similar to ones found in the Covid-19 virus.
Thanks to those antigens, a person's immune system learns how to fight the virus and neutralise Covid if it enters the body.
After the cells create these proteins, the body breaks down the mRNA instructions and gets rid of them.
Such direct communication with cells is revolutionary -- classic vaccines aimed to provoke an immune response by injecting a neutralised form of a virus or antigens into the system.
- Where did this come from? -
The first big breakthrough, in the late 1970s, was in using mRNA to make test-tube cells produce proteins.
A decade later, scientists were able to get the same results in mice, but mRNA still had two major drawbacks as a medical tool.
For one thing, cells in live animals resisted synthetic mRNA, provoking a dangerous immune response.
On top of that, mRNA molecules are fragile, making them difficult to deliver to the system without altering them.
In 2005, Kariko and Weissman of Penn State University published a groundbreaking study showing that a lipid -- or fat molecule -- envelope could safely deliver mRNA without negative effects.
The research caused a buzz in the pharmaceutical community and start-ups dedicated to mRNA therapies began to pop up around the world.
- What else can mRNA do? -
Scientists have worked on developing mRNA jabs for illnesses like seasonal flu, rabies and Zika, as well as those that have remained vaccine-resistant until now, including malaria and AIDS.
Researchers have also started testing personalised treatments on cancer patients, using samples of the proteins in their tumours to create specialised mRNA.
This then triggers the immune system to target specific cancer cells.
"The mRNA platform is versatile," University of Pennsylvania biochemist Norbert Pardi told AFP. "Any protein can be encoded as mRNA so there are many potential applications."
G.Stevens--AMWN